Galectin Therapeutics Inc.
GALT
$2.41
$0.010.42%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 30.74% | 8.57% | 7.89% | -7.71% | -11.42% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -48.37% | -72.92% | -53.70% | -59.04% | -18.15% |
| Operating Income | 48.37% | 72.92% | 53.70% | 59.04% | 18.15% |
| Income Before Tax | 47.61% | 54.04% | 27.06% | 39.20% | 16.17% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 47.61% | 54.04% | 27.06% | 39.20% | 16.17% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 47.61% | 54.04% | 27.06% | 39.20% | 16.17% |
| EBIT | 48.37% | 72.92% | 53.70% | 59.04% | 18.15% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 49.34% | 55.19% | 28.99% | 40.19% | 18.06% |
| Normalized Basic EPS | 49.68% | 55.45% | 29.22% | 40.34% | 17.86% |
| EPS Diluted | 49.34% | 55.19% | 28.99% | 40.19% | 18.06% |
| Normalized Diluted EPS | 49.68% | 55.45% | 29.22% | 40.34% | 17.86% |
| Average Basic Shares Outstanding | 4.08% | 3.18% | 3.09% | 1.95% | 1.98% |
| Average Diluted Shares Outstanding | 4.08% | 3.18% | 3.09% | 1.95% | 1.98% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |